B-MS to pay potential $499M settlement
USA-based drug major Bristol-Myers Squibb, the US Department of Justice and the Office of the US Attorney for the district of Massachusetts, say they have reached an agreement regarding the settlement of investigations involving B-MS' drug pricing, sales and marketing activities (Marketletters passim).
The framework, which is still subject to approval by the US Department of Justice, provides for a civil resolution, a payment of $499.0 million, with no criminal charges being brought against B-MS. The agreement also stipulates that the firm is to enter into a corporate integrity agreement with the Office of the Inspector General of the US Department of Health and Human Services.
Revised 2006 earnings forecast
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze